« September 2006 | Main | January 2007 »

October 26, 2006

eCheminfo Membership & Workshop Activity for 2007

During November I will be planning the 2007 programs for the eCheminfo Advanced Training Week in Oxford and the InterAction Meeting in Bryn Mawr.  Please contact me with your interests and proposals!

Latest Advances in Drug Discovery Design & Planning Methods
a Hands-on 5 Day eCheminfo Advanced Training Workshop Week
June 25-29, Chemical Research Laboratory, Oxford University, Oxford, UK

Latest Advances in Drug Discovery & Development
eCheminfo Community of Practice InterAction Meeting
15-18 October 2007, Bryn Mawr College, Philadelphia, PA, USA
Themes: Screening, Medicinal Chemistry, Drug Design, Toxicology, Structural Biology, Bioinformatics, Cheminformatics

eCheminfo Gold membership
This entitles members to access eCheminfo meeting proceedings including audio, access to our Executive Insights reports from meeting and community of practice activities, and additional member discounts on meeting and training registration fees. 

Download eCheminfo2007MembershipForm.pdf

Barry Hardy

October 25, 2006

Co-led Knowledge Management Training

As apparent from our discussions at Bryn Mawr College last week at the eCheminfo and InnovationWell meetings, knowledge management (KM) stands to play a key role in emerging new practices to drug discovery and development, healthcare and new services in personalised medicine.  However there is need to improve our understanding of and competency in KM and its emerging best practices to achieve breakthroughs such as innovation success in discovery, product development and improving confidence in safety.

A full five-day Certified Knowledge Manager (CKM) workshop will be held in Basel, 27 November – 1 December 2006.  The training will be jointly led for the first time by Swiss faculty who bring their own extensive experience of knowledge management and European practice to enrich the quality of the learning program.

The workshop week will be co-led by Douglas Weidner, President, International Knowledge Management Institute; Pavel Kraus, Founding Partner of aht'intermediation GmbH & President, Swiss Knowledge Management Forum; Beat Knechtli, Director and Chief Knowledge Officer, PwC Switzerland, and Barry Hardy, Director, KM Institute Switzerland

Case Studies & Discussions will be used to illustrate the application of KM principles and best practices.

More information is available at:
http://barryhardy.blogs.com/theferryman/2006/10/swiss_faculty_c.html

Barry Hardy

October 10, 2006

The emerging role of Metabolomics in Drug Development and Safety

Metabolomics is an FDA-identified Critical Path Opportunity offering a toolkit which can be potentially applied to identification of safety biomarkers, diagnostic monitoring of patient response to drug treatment, lead optimization through toxicity assessment in non-clinical drug development, biochemical pathway studies in cells, animals and humans, patient stratification, and insights on and tracking of mechanisms associated with the onset of disease or following therapeutic intervention.

However, despite its above promise, the challenges in the complexity of the biological systems studies, the experimental spectroscopy methods used and the datasets generated has restricted to this point the full commercial application of metabolomics methods in the pharmaceutical industry and in healthcare. 

The complexity of the interpretation of metabolomics data points to the need for improved data analytics and visualisation methods in decision making processes and situations.  The importance of the value-added of the integration of metabolomics data with other proteomic and genomic data to provide a more integrated, accurate and broader view of the state of the biological system studied points to the importance of explicit knowledge management techniques in critical path areas of clinical research and drug development to the application of semantic web, ontology and web service approaches and to the adoption of these approaches in the day-to-day scientific research activity as supported by electronic laboratory notebooks and collaboration systems.  It also points again to the importance of co-operation on the always difficult agreement area of the definition of standards and data integration.

Read more about this topic on The Ferryman at:
Metabolomics and its role in progressing Drug Development and Safety on FDA's Critical Path

http://barryhardy.blogs.com/theferryman/2006/10/metabolomics_an.html

Barry Hardy

October 06, 2006

Where do we currently stand with cheminformatics-driven medicinal chemistry?

On Wednesday 18 October 2006 at the eCheminfo Autumn InterAction Meeting we are convening a forum on Bench Scientists’ & Modellers’ Discussions on Discovery Tools & Modeling.

In this session a panel of experimental and computational chemists will discuss their experiences in using computational modeling methods in drug discovery. They will discuss where the methods and software are having success, and where current methods are not yet meeting their needs, are failing or have challenges or complications. Short presentations on drug discovery experiences will be used to seed discussion of cheminformatics-driven medicinal chemistry and lead optimization and conversations on where new developments could aid improvement in practice and tools.

The Panel consists of a group of experienced practitioners in both medicinal and computational chemistry: Osman F. Güner (Turquoise Consulting), James Arnold (AstraZeneca), Phil Edwards (AstraZeneca), Pete Connolly (Johnson & Johnson PRD), Michael Farnum (Johnson & Johnson PRD), and panel chair Jim Wikel (Coalesix).  This panel will seed discussions with presentations of the following experiences in drug discovery:

James Arnold (AstraZeneca), Use of computational techniques in the discovery of low molecular weight non-peptidic beta-secretase inhibitors: Application of fragment screening and structure-based design to identify and progress millimolar affinity hits to sub-micromolar leads

Phil Edwards (AstraZeneca), The Discovery of low molecular weight non-peptidic beta-secretase inhibitors: Application of fragment screening and structure-based design to identify and progress millimolar affinity hits to nanomolar leads

Pete Connolly (Johnson & Johnson PRD), New Tools for Structure-Activity Relationship Visualization: Applications to Drug Discovery

Michael Farnum (Johnson & Johnson PRD), Applying Chemical Intelligence to support Drug Discovery Researchers

Jim Wikel (Coalesix), Man, Machine & Drug Design

For abstracts of these presentations, please follow the continuation below.

Barry Hardy

(Continued….)

Continue reading "Where do we currently stand with cheminformatics-driven medicinal chemistry?" »

October 04, 2006

Could we take a Community Approach to Comparing Virtual Screening Methods?

John Irwin at UCSF, I and others working in the area of drug discovery have had several discussions and email exchanges on the topic of the performance and comparison of different virtual screening and docking methods on different targets and problems. 

The eCheminfo network supports community of practice activities, i.e., it is intended to support the activities of a group of people who bond together to share knowledge on good, better, and best practices, to learn skills from each other, share experiences, and engage in a process of collective learning.  It potentially then could be a neutral environment for supporting coordination on practice activities, such as the difficult area of comparative study in screening and docking.

We thought it would be useful to summarise some ideas on supporting greater collaboration on such work and to invite comments and discussion which we have done below.

Please contribute to the discussion and add your comments on the Cheminfostream Blog or John’s Docking.org blog.  (We can also be reached via email at barry.hardy [at] douglasconnect.com and jji [at] cgl.ucsf.edu.)  We look forward to your input.

Barry Hardy

Could we take a Community Approach to Comparing Virtual Screening Methods?

After twenty years of undeniable progress, molecular docking seems to have plateaued. A recent paper by Tirado-Rives and Jorgensen [1] dashes some of the few hopes we had left by showing that conformational energetics alone make it impossible to rank order diverse compounds in high throughput virtual screening. In a Perspective in the same issue [2], Leach, Shoichet and Pieshoff summarize the stagnating state of the art that is docking, and suggest a pragmatic way forward, through measurement and benchmarking. Again in the same issue, a laborious evaluation of 10 docking programs, using 37 scoring functions was applied to seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization [3]. Among some encouraging results and upbeat analysis, the paper makes a number of worrying observations, including that "high fidelity in the reproduction of observed binding poses did not automatically impart success in virtual screening". Moreover, for eight diverse systems, "no statistically significant relationship existed between docking scores and ligand affinity."

The physics of protein-ligand binding is clearly both important, and challenging. The NIH sponsored workshop described by Leach, Shoichet and Pieshoff [4] called for more high quality data to be made available for benchmarking, and, "well developed testing sets to be evaluated with all available technology, without barriers, if we are to see forward rather than lateral growth in the field."

Most efforts to compare docking methods in "apples-to-apples" comparisons have been plagued by one methodological weakness or another. For example, a common criticism is that the "experts" running the program are more familiar with one program than another. Criticisms of unfair bias due to past or ongoing association with a particular software group are frequent, particularly from the developers whose software performed worst. Numerous criticisms are also levelled at how success is judged, how the test sets are compiled, in fact, nearly everything about docking comparison studies can be criticised.

In the spirit of collaboration, and in an effort to move the field forward as advocated by NIGMS, we are suggesting here an "open source" initiative to compare docking methodologies (Our use of “open source” here is to the methods used to carry out comparisions of methods, not whether the source code used is “open source”). We propose that a form of peer review, as hosted on a wiki and supplemented by workshop activity or virtual conference-based discussion, be applied at all stages of a fair "competition", including the design of the experiment, collection of the data, running of programs, and the analysis of the results. The goal is not to show up one program or another as a winner or loser, but to honestly and fairly compare methods, allowing all reasonable criticisms to be raised during the process, so that the entire field can move forward.

The UCSF group are now offering a dataset which they recently compiled from the literature, in which they have attempted to design a database of actives and challenging decoys for 40 diverse targets [5]. They are also actively soliciting experimental test data from pharma. They know it is a challenge to get this data released, even for projects that are no longer active, but they are asking for it nonetheless, for the benefit of the field.

In the upcoming eCheminfo Community of Practice meeting in Bryn Mawr we have scheduled a forum (16.00 Tuesday 17th October) to discuss whether such an "open source" project to benchmark docking programs is of interest, and if so, how to best move forward. We think this is an auspicious time for such a project, and we hope you (and your company or organization) do too. The world has benefited enormously from other "open source" projects, such as Linux, MySQL, wikipedia, and so on. We think this is docking's time. What do you think?

As certainly not everyone interested in this topic can be present at the meeting in Bryn Mawr, and time there is limited, it would be good to have some exchange of ideas virtually in our run up to the meeting and beyond.

Barry Hardy (eCheminfo Community of Practice) and John Irwin (UCSF, Docking.org)

References
[1] Tirado-Rives & Jorgensen, Contribution of Conformer Focusing to the Uncertainty in Predicting Free Energies for Protein-Ligand Binding, J. Med. Chem, 2006, 59,5880-5884.
[2] Leach, Shoichet, Pieshoff, Prediction of Protein-Ligand Interactions. Docking and Scoring: Successes and Gaps., J Med Chem, 2006, 49, 5851-5855.
[3] Warren et al, A Critical Assessment of Docking Programs and Scoring Functions, J Med Chem, 2006, 49, 5912-5931.
[4] http://www.nigms.nih.gov/News/Reports/DockingMeeting022406.htm
[5] Huang, Shoichet, Irwin, Benchmarking Sets for Molecular Docking, J. Med. Chem, 2006, in press.

Communities of Practice

eCheminfo Chairs, Presenters & Instructors